HeyJaredRichard Mark Kirkner
- Indexed articles, last 90 days
- 9
- Latest publication
- Sep 2, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 17, 2026
Latest articles
How to Differentiate the Major Subtypes of ILD (opens the original)
Read excerpt
When the American Thoracic Society (ATS) and European Respiratory Society (ERS) last year came out with their joint statement on the classification of idiopathic interstitial pneumonias, it was the first update of the definitions of the subtypes of interstitial lung disease (ILD) in more than a decade and reflected how the thinking and management of the disease had evolved. The goal was to clearly define disease pathogenesis and biology, said Kerri Johannson, MD, associate professor at the Cummi
Branded Bevacizumab: Retina Breakthrough or Bankbuster? (opens the original)
Read excerpt
For two decades, off-label bevacizumab has been a cheap and widely effective mainstay of the ophthalmologist’s toolbox for the treatment of retinal diseases. The FDA changed that paradigm in July when it approved a new formulation of bevacizumab made specifically for the eye for the treatment of neovascular age-related macular degeneration (nAMD), but not for any of the other retinal diseases for which the drug has been used. The off-label bevacizumab ophthalmologists use has been repackaged fro
VNS for RA a Year After Approval: Where Do Things Stand? (opens the original)
Read excerpt
CORRECTED August 19, 2026 // An earlier version of this article misstated how many implantation procedures had been performed in the year since the device was approved and how much time patients must wear the device's recharging collar per week. A statement that described the percentage of implant recipients who had stopped taking RA medications by year 2 was also removed. Ann Igoe, MD, has lived with debilitating rheumatoid arthritis (RA) since she was a 10-year-old girl in Ireland, but since s
Statins Tied to Fewer Failures After Retina Fixes (opens the original)
Read excerpt
People who undergo surgical repair for retinal detachment and take statins had about half the risk for complications from the operation, according to a retrospective analysis of 20 years of data from a national database of electronic medical records. Patients taking statins had a 47% lower risk for proliferative vitreoretinopathy (PVR) — an incidence of 1.75% vs 3.3% for nonstatin users — and a 48% lower risk for requiring a repeat surgery for complex retinal detachment — an incidence of 3.24% v
Gene Therapy Delivers Sustained Retinal Protection (opens the original)
Read excerpt
The investigational gene therapy ixoberogene soroparvovec (Ixo-vec) helped patients maintain vision and left active levels of the therapeutic protein in the eye 5 years after an initial injection, according to results of an extension trial presented at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting in Montreal. The drug, a long-term treatment for neovascular age-related macular degeneration (AMD), also significantly reduced the need for supplemental injections. “For a firs
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.